The Brand New Test That Predicts Breast Cancer’s Return

 

Hamilton hospital uses test to predict radiation outcomes for breast cancer patients

Video taken from the channel: LOCAL 12


 

Breast Cancer Recurrence Test

Video taken from the channel: CBS News


 

Is There a Test That Can Predict Breast Cancer Recurrence?

Video taken from the channel: Breast Cancer Answers®


 

Gene Profile May Predict Breast Cancer Return

Video taken from the channel: MDedge: news and insights for busy physicians


 

Simple blood test may predict recurrence of some breast cancers

Video taken from the channel: WXYZ-TV Detroit | Channel 7


 

New blood test predicts breast cancer’s return at start of treatment

Video taken from the channel: The Institute of Cancer Research, London


 

New Blood Test For Breast Cancer Recurrence!

Video taken from the channel: Breast Cancer Answers®


New blood test predicts breast cancer’s return at start of treatment by Institute of Cancer Research Credit: CC0 Public Domain A new blood test for women with breast cancer can predict how well. Breast cancer sufferers have their DNA scanned by scientists in order to better understand the genetic cause of cancer (Getty) Scientists have found a way of testing whether a person’s breast. Pioneering test can predict whether breast cancer will return and could be used to save lives in future The method works around scanning for ‘hotspots’ of immune cells in tumours Patients are 25% more likely to relapse within 10 years if they have them The likelihood of cancer returning within five. New blood test predicts breast cancer’s return at start of treatment Published: Jun 06, 2019 A new blood test for women with breast cancer can predict how well patients will respond to a new drug right at the start of treatment.

A new blood test could help predict whether women with breast cancer will respond to treatment before it begins. Scientists at London’s Institute of Cancer Research said the “liquid biopsy” can detect genetic changes in the tumours of patients and indicate if they are less likely to respond to a new targeted drug. A new blood test for women with breast cancer can predict how well patients will respond to a new drug right at the start of treatment. The new blood test detected genetic changes within women’s breast cancers which indicated that these patients were less likely to respond to treatment – and that their disease could be expected.

A new blood test that detects genetic changes in tumours could help predict whether women with breast cancer will respond to treatment before it begins. TUESDAY, Feb. 6, 2007 (HealthDay News) The U.S. Food and Drug Administration has approved a test designed to predict the chances of breast cancer returning or spreading within five to 10 years after a woman’s initial cancer.

Blood test could predict breast cancer’s return: study The technology, described in the journal Science Translational Medicine, works by detecting cancer DNA that circulates in the bloodstream. Predict is an online tool that helps patients and clinicians see how different treatments for early invasive breast cancer might improve survival rates after surgery. It is endorsed by the American Joint Committee on Cancer (AJCC).

List of related literature:

In this group, we can expect that one woman will have breast cancer, and there is a 100% certainty that the test will be abnormal for hera true positive test result.

“Cognitive Errors and Diagnostic Mistakes: A Case-Based Guide to Critical Thinking in Medicine” by Jonathan Howard
from Cognitive Errors and Diagnostic Mistakes: A Case-Based Guide to Critical Thinking in Medicine
by Jonathan Howard
Springer International Publishing, 2018

There are an estimated 246,660 new breast cancer cases that will be diagnosed in women during 2016 [64], and according to the Surveillance, Epidemiology, and End Results Program (SEER) data, there are currently 3.1 million breast cancer survivors in the United States [65].

“Lymphedema: A Concise Compendium of Theory and Practice” by Byung-Boong Lee, Stanley G. Rockson, John Bergan
from Lymphedema: A Concise Compendium of Theory and Practice
by Byung-Boong Lee, Stanley G. Rockson, John Bergan
Springer International Publishing, 2018

This testing is recommended for women with a 20% or greater chance for the development of breast cancer in their lifetimes.

“Adult Health Nursing E-Book” by Kim Cooper, Kelly Gosnell
from Adult Health Nursing E-Book
by Kim Cooper, Kelly Gosnell
Elsevier Health Sciences, 2018

The expected outcomes for these strategies depend on each test’s sensitivity and specificity for detecting breast cancer, which is influenced in turn by other factors, such as the frequency with which the test is performed.

“Goldman-Cecil Medicine E-Book” by Lee Goldman, Andrew I. Schafer
from Goldman-Cecil Medicine E-Book
by Lee Goldman, Andrew I. Schafer
Elsevier Health Sciences, 2015

Yet studies suggest that the breast exams performed by a physician account for another 5 percent of breast cancers detected—given the number of breast cancers in this country, that comes out to ten thousand cancers picked up on exam every year, making touch a surprisingly powerful tool as well.

“Every Patient Tells a Story: Medical Mysteries and the Art of Diagnosis” by Lisa Sanders
from Every Patient Tells a Story: Medical Mysteries and the Art of Diagnosis
by Lisa Sanders
Potter/Ten Speed/Harmony/Rodale, 2009

Oktay Kutluk

Kutluk Oktay, MD, FACOG is one of the world's foremost experts in fertility preservation as well as ovarian stimulation and in vitro fertilization for infertility treatments. He developed and performed the world's first ovarian transplantation procedures as well as pioneered new ovarian stimulation protocols for embryo and oocyte freezing for breast and endometrial cancer patients.

Mail: [email protected]
Telephone: +1 (877) 492-3666

Biography: https://medicine.yale.edu/profile/kutluk_oktay/
Bibliography: oktay_bibliography

View all posts

2 comments

Your email address will not be published. Required fields are marked *

  • Dr. Jay Harness recently spoke with André de Fusco, CEO of Cynvenio, about his company’s new diagnostic test, ClearID for Breast Cancer, and how he sees it revolutionizing the world of cancer treatment. ClearID is a blood test that measures cancer cells to see if a woman could be suffering breast cancer recurrence, and can often detect the recurrence before mammography is able to.

  • Very informative upload MammaPrint is a breast cancer recurrence test that helps patients and their doctors determine the best type of breast cancer treatment is right for them, just as you discussed. Because of the test, patients can narrow down that decision whether or not a certain treatment would be best.

    agendia*com